Santen Pharmaceutical Co., Ltd.
https://www.santen.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Santen Pharmaceutical Co., Ltd.
ASCO 2023 – Deep And Early Responses Lift Hopes At Effector
New data with a novel RNA translation regulator gave the stock a pre-ASCO boost, but the micro-cap company needs to keep the momentum going.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a Pink Sheet analysis of FDA approval decisions since 2021.
How Sturdy Is PK/PD Bridge Between Epinephrine Injection Products And Nasal Spray?
FDA enumerates uncertainties in determining whether PK/PD results support a favorable risk-benefit assessment for use of ARS Pharmaceuticals’ epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
-
Medical Devices
- Biomaterials
- Implantable Devices
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Eyevance Pharmaceuticals LLC.
- Novagali Pharma SA
- Santen Inc.
- Chongqing Santen Kerui Pharmaceutical Co., Ltd
- InnFocus Inc,
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice